This is MEDIVIR OUR research is based on the know how of proteases and polymerases. The aim is to have a steady flow of CDs into clinical development.

Slides:



Advertisements
Similar presentations
Overview of the Keys to Successful Commercialization Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. Tucson, Arizona October 18, 2001.
Advertisements

1 Increasing Biotech Involvement in Global Health Innovation Oxford Conference on Innovation and Technology Transfer for Global Health September 11, 2007.
The Drug Discovery Process
Fundraising. Starting and growing a business always require capital. There are a number of alternative methods to fund growth. These include the owner.
TBD-UK: The UK response in the discovery and development of new TB drugs. Dr Geoff Coxon Deputy Leader & Director of Medicinal Chemistry, TBD-UK APPG-TB.
Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
Agenda Overview: the Bio-Pharma industry Major challenges for developers Genzyme: Innovations for unmet medical needs.
Targeted Cancer Therapeutics, LLC Investor Presentation.
Investor Presentation | October 2013 The future of drug discovery has arrived Reducing development time, cost & risk.
The presenters from Medivir at the Carnegie lunch January 21 Lars Adlersson CEO Prof Bertil Samuelsson, VP Discovery and Research Rein Piir, CFO / IR.
1 ICON Plc. Merrill Lynch - Global Pharmaceutical, Biotech & Medtech Conference, September 19 th 2007.
Galapagos: a new force in drug discovery Onno van de Stolpe – CEO IEX Beleggen in Biotech Dag May 20, 2006.
Establishing Preclinical Development Operations in China Ming Guo, Ph.D. VP Pharmaceutical Sciences & Manufacturing SABPA Pacific Forum Nov. 4, 2006.
Forum On Financing Biotechs: Partnering The Biotech Perspective May 15, 2002 Celia Courchene VP, Business Development Xenon Genetics Inc. The Biotech Perspective.
Medivir AB Carnegie Health Care Seminar May 2007 Lars Adlersson, CEO & President Börje Darpö, VP Development Rein Piir, CFO / IR.
Company Presentation Summer Medivir in brief One of the world leaders in polymerase research. Aiming for a similar position in protease research.
Medivir AB Aktiespararna i Norrköping 18 April 2007 Rein Piir, CFO / IR.
Workshop ”InDeCS-H: Development of Healthcare Biotechnology SMEs“ 10th September 2009 Budapest Strategy for Hungarian pharmaceutical and biotechnology.
SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Partnerships & Alliances Molecular Diagnostics Prof. K. K. Jain MD, FRACS, FFPM CEO, Jain PharmaBiotech Blaesiring 7, 4057 Basel, Switzerland Colloquim.
Academic Clinical Trial Do’s & Don’ts for Partnering with Pharma CCAF San Diego, CA April 14, 2014 J. Eric Bubbers, Ph.D.
Flinders Technologies Pty Ltd Copyright © 2002 J V Turner WIPO/INV/BEI/02/7.a Universities and R&D organizations are potential sources of valuable intellectual.
1 Global New Employee Orientation Workshop Welcome.
Stages of drug development
Equity Financing for High Growth
RSA – Accenture Insurance Solution
OPIM 5894 Advanced Project management Vertex Pharmaceuticals case
Technology Transfer from the Weizmann Institute of Science Yeda Research & Development Co. Ltd. w w w. Y e d a R n D. c o mw w w. Y e d a R n D. c o m.
”We aim to be the preferred life sciences investment company in Northern Europe…” “We have the people, the differentiation, the mind-set, and the structure.
Medivir September 2007 Lunch presentation at SHB CEO Lars Adlersson VP Research Bertil Samuelsson CFO / IR Rein Piir.
Phylogica Ltd ASX: PYC Doug Wilson
1 3 RD Annual TBI Monique Létourneau Executive Vice-President & CFO September 21, 2007.
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
Asia’s Largest Global Software & Services Company Genomes to Drugs: A Bioinformatics Perspective Sharmila Mande Bioinformatics Division Advanced Technology.
1 Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property Frank S. Castellana, M.D., Eng.Sc.D.
Medivir AB Acumen BioFin 4th Annual Global Healthcare Conference Lars Adlersson, CEO & President.
Priority Medicines Project Background review Tuberculosis Dr Mary Moran London School of Economics September 2004.
Medivir in Brief Swedish Biotech Transforming into a Pharmaceutical Company Publicly listed on OMX Stockholm, headquartered in Huddinge, Sweden Spun-out.
1 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2008 Dr. John Climax Executive Chairman.
Dr Caroline Barelle MBA Giving birth to a biotech where’s the pain relief ?!
Managing Medical R&D Defining and Realizing Clinical and Commercial Value David J. Wierz Senior Director Commercial Investment & Pricing Strategy Wyeth-Ayerst.
Corporate Presentation Q4 FY Disclaimer Certain statements in this release concerning our future growth prospects are forward-looking statements,
Copyright Rib-X, Inc – All Rights Reserved Susan Froshauer, Ph.D. President and CEO.
Milan, 9 May Building Value. Milan, 9 May 2001 Giovanni Recordati Giovanni Recordati Chairman and Chief Executive Officer Chairman and.
0 15 July The SKF Group Half-year results 2008 Tom Johnstone, President and CEO.
Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.
Developing medicines for the future and why it is challenging Angela Milne.
Strategies for developing India as a contract research hub Swaminathan Subramaniam Chief Operating Officer Aurigene Discovery Technologies.
PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.
1 ICON Plc. Raymond James – 30 th Annual Institutional Investors March 11 th 2009.
ExpressOn BioSystems Access to molecular technology Products and services for the cutting edge of bio-science research and therapeutics CIC2000 Dr. Peter.
MRC Technology an independent life science medical research charity Biotech & Money 2016 Mr Andrew Mercieca, Director of Finance
New Treatments to Reverse the Tide of TB Maria C. Freire, Ph.D. CEO & President.
UCB Inspired by patients. Driven by science.
BioMarker Strategies biotrinity 2016 London April Functional Profiling to Guide Cancer Drug Development and Treatment Selection.
A model collaboration using the Pool Susanne Hollinger, Ph.D., J.D. Chief Intellectual Property Officer Emory University.
26th April 2016, BioTrinity - London
A truly integrated drug discovery company 26 th April 2016 CONFIDENTIAL.
SwedenBIO Wallingatan 24 S Stockholm Office An analysis of the clinical development pipeline in the Swedish biotech industry Feb,
1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.
Success Stories of Globalization in Korean Pharma
May 2016.
Universities and the Commercial World
Gestora brasileiro focada exclusivamente na área da saúde.
The presenters from Medivir at the Carnegie lunch January 21 Lars Adlersson CEO Prof Bertil Samuelsson, VP Discovery and Research Rein Piir, CFO /
Medivir in Brief Swedish Biotech Transforming into a Pharmaceutical Company Publicly listed on OMX Stockholm, headquartered in Huddinge, Sweden Spun-out.
Drug Design and Drug Discovery
M.D. – New Business and Partnerships
Global Specialty Pharmaceuticals Market. Report Description and Highlights According to Renub Research report "Specialty Pharmaceuticals Market, by Country.
Presentation transcript:

This is MEDIVIR OUR research is based on the know how of proteases and polymerases. The aim is to have a steady flow of CDs into clinical development. WE focus on mainly two therapeutic areas; infectious and immunological diseases. OUR pipeline is balancing commercial opportunities and development risks. WE are one of the largest biotech companies in Europe in terms of pipeline and employees, located in Cambridge (UK) and Huddinge (SE). WE own CCS, a specialty pharma company. Most likely to have one product to launch in 2005.

Medivir has a broad know how in these enzymes, enabling a variety of research options and still be focused. Proteases and polymerases represent major pharmaceutical opportunities

CD = Candidate DrugNNRTI = Non Nucleoside Reverse IND = Investigational New Drug Transcriptase Inhibitor SBDD = Structured Based Drug Design PI = Protease Inhibitor Pre-clinical Discovery in Medivir Infectious and immunological diseases Target Identification Hit Identification Lead Identification Lead Optimisation CD NominationCD IND IND X-ray Structure Protease & polymerase compound libraries Prodrugs RAPiD TM Hits Robust Leads CD SBDD Combinatorial Chemistry DMPK FOCUS TM XED n Improved capacity and shorter time to CD Validation - protease gene family polymerases - polymerases Screening Identification RAPiD TM FOCUS TM

High activity in operations : Positive results for Medivir’s HIV and hepatitis B antiviral MIV-210 presented at ICAAC : Change of CEO at Medivir : A phase IIa clinical study with Medivir’s compound MIV-310 shows a major antiviral effect in patients with multi drug resistant HIV : Proof of principle in research on treatment of multiple sclerosis (MS) : Change in the Medivir HIV program : Medivir signs agreement to out-license its novel HIV/AIDS treatment to Roche : Medivir and Reliant Pharmaceuticals form strategic alliance : Medivir and Peptimmune announce break-trough research on treatment of rheumatoid arthritis : Medivir’s HIV research programme designates Candidate Drug.

Status October 2002 Partnership and deal values Partnership and deal values Deal values for existing partnerships amounts to SEK 700 million (refers to 3 deals) of which SEK 100 million is down payments to be accounted as revenues during Cash wise, Medivir has received SEK 80 million of these during H Medivir has retained the Nordic marketing rights for RP-606 and MV Corporate Peptimmune 50/50 ”joint venture” for Cathepsin S in late pre-clinical research. Chiron for Hepatitis C in pre-clinical discovery. Roche for HIV-NNRTI in late pre-clinical development. Reliant in RP-606 (Shingles) on its way to phase III. University University of Dundee – AEP, autoimmune disorders, in early pre-clinical discovery. St:George (London, UK) – Cathepsin K, osteoporosis, in pre-clinical lead identification phase. MRC (London, UK) – broad anti-bacterial program, in early pre-clinical discovery. Karolinska Institute – Alzheimer disease, in pre-clinical discovery. Agrivir – Joint venture med BioAgri. And several other universities in Sweden, US and UK.

Status October 2002 Financial The group, period ending 30 June Profit after financial items amounted to SEK 4,3 (-68,0) million. Cash SEK 195 million. Going forward, the R&D expenditure will be in the range of MSEK on a rolling 12 month average. CCS, a strategic and financial asset to Medivir Net sales SEK 76,7 (63,8) million during H1 (2002); SEK 9,7 (9,7) million profit. Cash positive operations. CCS had extraordinary costs amounting to MSEK 4,5 during H1 (2002) for investments for the coming AstraZeneca production. Significant increase in sales, profit and “market cap” predicted over next years from both internal activities and by aggressive acquisition strategy.

Status October 2002 Pipeline Varity of projects focusing on; HIV, Hepatitis, Cold sores, Shingles, MS, RA and Osteoporosis of which; »4 projects in clinical development »4 late stage pre-clinical projects »More than 10 discovery activities

Status clinical projects RP Shingles: Licensed to reliant in February. Transfer of project completed in May. Planning and development work ongoing towards phase III studies. Waiting for the end of phase II meeting with FDA. ME Cold sores: Seeking partnership in order to conduct phase III studies. MIV HIV: Phase IIa results reported during summer. Planning for phase IIb studies and seeking partnership in parallel. MIV-210 – Hepatitis B and HIV: Results from pre-clinical studies reported at ICAAC in September. Ongoing phase I trails and planning for phase IIa studies, both for Hepatitis B and HIV. (MV – Licensed to Roche in April. Transfer of project completed in June. Now in late pre-clinical development towards clinical trails during 2003.)

Late Pre-clinical projects October 2002 Hit Identification Lead Identification Lead Optimisation Project Indication NNRTI -polymerase inhibitor HIV-protease inhibitor Cathepsin S -protease inhibitor Cathepsin K -protease inhibitor CD HIV-AIDS e.g. astma, MS, RA, GVHD Osteoporosis

Medivir’s strategy going forward

Strategy going forward 2003 Mainly two internal clinical programs ongoing, MIV-310 and MIV-210. The aim is to find partners for all clinical projects. The aim is to balance risk/benefit in an optimal way. Secure the Nordic rights in future partnerships. Use CCS as a financial asset and develop it accordingly. Continue aggressive “Key Account Management”. Continue the focusing process in order to increase research capacity to speed up several promising pre-clinical activities and projects. Add pre-clinical collaborations and partners. Add new targets. Expand size and coverage of protease and polymerase inhibitor libraries by building up of matrix metallo & serine protease inhibitor library. Position Medivir as the preferred partner in protease and polymerase research.

Medivir as an investment ”Well positioned for success and value creation” Medivir is one of the largest biotech companies in Europe in terms of pipeline and personnel. Is establishing itself as the research driven small pharmaceutical company. CCS is a strategic asset in this process. Large scientific and commercial opportunities in pipeline. Solid financial position including opportunities in late stage clinical projects. Existing and future partnerships will secure speed of development adding value to the shareholders. Most likely to have one product to launch in 2005.